Results 11 to 20 of about 4,156,285 (177)

PIVKA-II but not dp-ucMGP is associated with aortic calcification in chronic kidney disease [PDF]

BMC Nephrology
Background Patients with chronic kidney disease (CKD) are susceptible to vascular calcification and vitamin K deficiency. Matrix gla protein (MGP) is a potent inhibitor of calcification requiring vitamin K for activation.
Jakob Nyvad, Kent Lodberg Christensen, Gratien Andersen, Mark Reinhard, Bjarne Linde Nørgaard, Jonna Skov Madsen, Sebastian Nielsen, Martin Bjergskov Thomsen, Jesper Møller Jensen, Christian Daugaard Peters, Niels Henrik Buus   +10 more
doaj   +3 more sources

Early PIVKA-II Response Associated with Treatment Efficacy and Survival Outcomes for Patients with Advanced Hepatocellular Carcinoma Receiving Immune Checkpoint Inhibitors and Targeted Therapy [PDF]

Journal of Hepatocellular Carcinoma
Zheng-Kang Fang,1,2 Yu-Ting Xiao,1 Xia Feng,1 Zhe-Jin Shi,1,3 Si-Yu Liu,4 Yang Yu,5 Li-Ming Jin,1 Dong-Sheng Huang,1 Cheng-Wu Zhang,1 Jun-Wei Liu,1 Lei Liang1 1Department of General Surgery, Cancer Center, Hepatobiliary & Pancreatic Surgery and ...
Fang ZK, Xiao YT, Feng X, Shi ZJ, Liu SY, Yu Y, Jin LM, Huang DS, Zhang CW, Liu JW, Liang L   +10 more
doaj   +4 more sources

Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma. [PDF]

Cancers (Basel)
Background and Aims: Hepatocellular carcinoma (HCC) represents the second leading cause of cancer deaths worldwide. Six-month imaging along with alpha-fetoprotein (AFP) serum levels detection are the current gold standard to exclude HCC. Protein induced by vitamin K absence (PIVKA-II) has been proposed as a potential screening biomarker for HCC.
Guarneri V, Loggi E, Ramacieri G, Serra C, Vukotic R, Vitale G, Scuteri A, Cursaro C, Margotti M, Galli S, Caracausi M, Brodosi L, Gabrielli F, Andreone P.   +13 more
europepmc   +6 more sources

Primary colon cancer with a high serum PIVKA-II level

International Journal of Surgery Case Reports, 2015
Abstract Introduction Protein induced by vitamin K absence/antagonist-II (PIVKA-II) is an abnormal protein, and several reports have demonstrated the efficacy of PIVKA-II in the diagnosis of hepatocellular carcinoma (HCC).
Kazuya Kato, Yoshiaki Iwasaki, Kazuhiko Onodera   +2 more
exaly   +4 more sources

Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study [PDF]

Scientific Reports
Protein induced by vitamin K absence or antagonist II (PIVKA-II) plays a critical role in the diagnosis of hepatocellular carcinoma (HCC), however, studies on its efficacy in diagnosing recurrent HCC were rarely found.
Wenfeng Zhu, Weilong Wang, Wenjie Zheng, Xiaolong Chen, Xiaowen Wang, Juping Xie, Shijie Jiang, Haoqi Chen, Shuguang Zhu, Ping Xue, Xiaofeng Jiang, Hua Li, Genshu Wang   +12 more
doaj   +3 more sources

Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis

International Journal of Biological Markers, 2018
Background: Several studies have been conducted to evaluate the prognostic value of prothrombin induced by vitamin K absence-II (PIVKA-II) overexpression in hepatocellular carcinoma patients treated with curative ablation.
Zhihong Liu, Xueru Yin, Xiaolong Qi
exaly   +3 more sources

Investigation of Serum PIVKA-II Levels in Patients with Helicobacter pylori Infection and Normal Group [PDF]

Iranian Journal of Colorectal Research, 2023
Background: Helicobacter pylori is a highly prevalent microorganism and risk factor for gastric cancer. In this study, we evaluated the serum levels of PIVKA-II in patients with and without H.
Seyedeh Azra Shamsdin, Hassan Akrami, Yousef Nikmanesh, Hasti Samani, Mahammad Javad Fattahi   +4 more
doaj   +2 more sources

Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients

Medicina, 2022
Background and Objectives: We aim to compare the diagnostic performance of Protein induced by vitamin K absence-II (PIVKA-II), a biomarker for hepatocellular carcinoma (HCC), and alpha-fetoprotein (AFP) in differentiating HCC and non-malignant high-risk (
Hana Hadi, Wan Muhammad Azfar Wan Shuaib, Raja Affendi Raja Ali, Hanita Othman   +3 more
doaj   +2 more sources

Levels of PIVKA-II and alpha-fetoprotein in unresectable hepatocellular carcinoma compared to healthy controls and predictive values of both markers with radiological responses after loco-regional interventions [PDF]

PeerJ, 2023
Background The significance of the current study was to determine normative levels of PIVKA-II and AFP in patients with unresectable HCC and healthy participants.
Norhanan Hamzah, Nur Karyatee Kassim, Julia Omar, Mohd Shafie Abdullah, Yeong Yeh Lee   +4 more
doaj   +3 more sources

Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data

BMC Cancer, 2017
Background Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is an efficient biomarker specific for hepatocellular carcinoma (HCC). Some researchers have proved that levels of PIVKA-II reflect HCC oncogenesis and progression.
Rentao Yu, Zhaoxia Tan, Xiaomei Xiang, Yunjie Dan, Guohong Deng   +4 more
doaj   +2 more sources